Michelle Fay Cortez
Amarin's 475% Surge Leaves Its Holders Flush and Sellers Crushed
Roche Left Seeking a Niche as Merck Dominates Lung-Cancer Market
Vericel’s FDA-approved MACI procedure has a small but valuable audience.
Medtronic Agrees to Buy Mazor Robotics in $1.6 Billion Deal
This Cartridge of Plastic Beads Can Filter Blood During Surgery
Liu Qiangdong flew home to China not long after his arrest, raising questions about why he was freed so quickly.
A Year After Cancer Milestone, Novartis’s Barrett Talks Next Steps
U.S. FDA is warning doctors, patients that few widely used diabetes drugs may, in some rare cases, cause a Fournier’s gangrene.
Suicides and deaths from drug overdoses are killing more people in the U.S. than diabetes is.
The $250 Biohack That’s Revolutionizing Life With Diabetes
The biggest technical hurdle for Onpattro was getting it into the liver cell’s cytoplasm.
Alnylam Wins First U.S. Drug Approval in Rare Genetic Disease
ICU Medical Drops After Report Smiths May Walk From Deal Talks
Alzheimer's Study Lacks ‘Shock and Awe’ Biogen Investors Sought
Biogen, Eisai drug slows Alzheimer’s disease by 30 percent, studies say.
Lowering Your Blood Pressure Could Stave Off Dementia
Biogen Awaits Crucial Alzheimer's Results as Earnings Beat
Drugmaker Backs Off Plan to Charge for Unproven ALS Therapy
The Price to Try a Drug Could Be $300,000 for Dying Patients
Finding Cancer Patients Is Pharma Industry's Unlikely Challenge
Dying Patients Face Reality Check on Right to Try